# OnCo record revumenib (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/revumenib/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "revumenib" ;
  schema:name "Revumenib"@en ;
  schema:description "Revumenib (Revuforj) is the first menin inhibitor (2024), for acute leukaemias with KMT2A rearrangements or NPM1 mutations."@en ;
  schema:url <https://onco.cc/drugs/revumenib/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Revumenib> ;
  owl:sameAs <http://www.wikidata.org/entity/Q131320680> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Revumenib> ;
  onco:status "approved" ;
  onco:modality "Small-molecule menin inhibitor" ;
  schema:alternateName "Revuforj" ;
  onco:approval "US 2024: Relapsed/refractory KMT2A-rearranged acute leukaemia, age ≥1", "US 2025: Relapsed/refractory NPM1-mutant AML" ;
  onco:related <https://onco.cc/biomarkers/npm1-mutation/> ;
  onco:cancers <https://onco.cc/cancers/aml/>, <https://onco.cc/cancers/all-leukemia/>, <https://onco.cc/cancers/aml-npm1-kmt2a/> ;
  onco:technologies <https://onco.cc/technologies/epigenetic-drugs/> ;
  onco:targets <https://onco.cc/targets/menin/> ;
  onco:companies <https://onco.cc/companies/syndax/> ;
  onco:pathways <https://onco.cc/pathways/menin-kmt2a/> ;
  onco:trials <https://onco.cc/trials/nct07211958/> .